Completed PHASE4 INTERVENTIONAL 1-arm NCT01087840

Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men (RAL-NPEP)

Safety, Tolerability, and Adherence to a Raltegravir-based Antiretroviral Regimen for HIV Non-occupational Postexposure Prophylaxis

Sponsor: Andrew Carr

Conditions HIV Infections HIV Prevention

Interventions Raltegravir

Updated 6 times since 2017 Last updated: Apr 15, 2014 Started: Jul 31, 2010 Primary completion: May 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on HIV Infections and HIV Prevention, this trial is completed. The trial is conducted by Andrew Carr and has accumulated 6 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jun 2022 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Jun 2022 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Andrew Carr
Merck Sharp & Dohme LLC

Data source: St Vincent's Hospital, Sydney

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia